This scoping review aims to consolidate evidence on the experiences of cancer patients undergoing chemotherapy in oncology facilities across sub-Saharan Africa, highlighting common physical, psychological, and social challenges and identifying under-researched areas for future study.
March 2026 in “Cancer Diagnosis & Prognosis” In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.
January 2026 in “European Journal of Cancer Care” In this cross-sectional study, social support was found to improve empowerment and alopecia-related quality of life in breast cancer patients, with an indirect benefit on quality of life achieved through enhanced empowerment.
11 citations
,
September 2024 in “Journal of Advanced Research” This study found that PC 3DP models are reliable preclinical tools that could potentially customize treatment strategies and predict patient prognoses by correlating drug sensitivity profiles with clinical outcomes, though larger patient cohort validation is needed to confirm clinical utility.
15 citations
,
March 2018 in “Cancer Medicine” This study found that alopecia areata patients had a slightly decreased overall cancer risk, with significantly lower risks for some cancers but higher risks for lymphoma, breast, kidney, and urinary bladder cancers.
